Form 4: ALX Oncology Chief Medical Officer Alan B. Sandler Acquires 600,000 Stock Options

Alan B. Sandler, Chief Medical Officer of ALX Oncology Holdings Inc., was granted 600,000 employee stock options on November 18, 2024.

Summary

• Alan B. Sandler, the Chief Medical Officer of ALX Oncology Holdings Inc., acquired 600,000 employee stock options on November 18, 2024.
• The exercise price of these options is $1.22 per share.
• The options vest over time, with one-fourth vesting on November 18, 2025, and the remaining vesting monthly over the following 48 months.
• The options expire on November 17, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There is no indication of any negative sentiment.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of one-fourth after one year and the remainder over the following 48 months is a typical vesting schedule.
• The exercise price of $1.22 is likely based on the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant may have a slightly dilutive effect on existing shareholders if the options are exercised.
• The grant incentivizes the Chief Medical Officer to work towards the long-term success of the company, which benefits all stakeholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, ALX Oncology, ALXO, Chief Medical Officer, Alan B. Sandler, equity